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Abstract
Background: Along with general measures of treatment satisfaction, treatment-specific and device-specific
treatment satisfaction should be assessed in clinical trials, because these latter measures may be more strongly
correlated with clinical outcomes.
Methods: Study participants were 1076 adults (type 1 = 509, type 2 = 567) in clinical trials of Technosphere
Insulin®, who completed the SF-36 health-related quality of life questionnaire and the Inhaled Insulin Treatment
Questionnaire (IITQ), a new instrument assessing diabetes worries, perceptions of insulin therapy, treatment
satisfaction, treatment preference, and inhaler performance. The IITQ was administered twice prior to treatment
initiation in the clinical trials, 1-2 weeks apart, and several times during the trials. Inhaler performance was assessed
at follow-up visits, after participants had used the device.
Results: IITQ subscales had acceptable reliability (alpha = 0.68-0.87, median 0.83) and test-retest correlations (intra-
class correlation coefficient = 0.67-0.90, median 0.82); floor effects (0.2-2.8%) and ceiling effects (0-9.3%) were
minimal. Reliabilities for inhaler performance measures were acceptable (alpha = 0.73-0.90, median 0.85); there
were no floor effects (0.0%) and ceiling effects (4.9-39.0%) were moderate. There were several modest associations
between IITQ scores and measures of health status. Diabetes worries were lower for participants who had better
mental health (type 2) and for those with higher BMI; perceptions of insulin therapy were more favorable for
participants who had better physical and mental health; treatment satisfaction was higher for patients who had
lower BMI (type 2), lower A1c levels, and better physical health (type 2); treatment preference was higher for
patients with lower BMI (type 2) and better mental health (type 1).
Conclusions -: Preliminary findings suggest that the IITQ is a comprehensive, reliable measure of the experience of
patients treated with inhaled insulin.
Background
Patient-reported outcomes (PRO) are now accepted as
important outcomes in assessing the effects of new
therapies because PRO may affect treatment adherence
[1] and consequent clinical outcomes [2-4]. An instru-
ment for assessing PRO is valuable to the extent it reli-
ably, validly, and comprehensively assesses the benefits
and burdens of a specific therapy. A comprehensive
assessment of PRO should include measures of general
concerns (e.g., diabetes-related worries), treatment-spe-
cific measures (e.g., perceptions of insulin therapy), and
treatment satisfaction and treatment preference, as well
as device-specific measures when applicable (e.g., insulin
delivery system perceptions). Comprehensive diabetes
treatment satisfaction instruments include the Insulin
Delivery System Rating Questionnaire (IDSRQ) [5] and
the Pramlintide Treatment Satisfaction Questionnaire
(PRAM-TSQ) [6].
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should be included in assessment instruments because
t h e ym a yb em o r es t r o n g l yc o r r e l a t e dw i t hc l i n i c a lo u t -
comes than more general diabetes treatment satisfaction
measures [7]. Thus more specific measures may be
more responsive to differences among treatments. For
example, a question such as “how much does your insu-
lin delivery system interfere with your ability to get a
good night’ss l e e p ? ” ( f r o mt h eI D S R Q ) ,i sl i k e l yt ob e
more sensitive to differences among insulin delivery sys-
tems than a question such as “how satisfied are you
with your understanding of diabetes? (from the Diabetes
Treatment Satisfaction Questionnaire) [8].
The Inhaled Insulin Treatment Questionnaire (IITQ)
was developed to meet the goal of creating a single ques-
tionnaire that assessed the broad range of patient-
reported outcomes relevant to use of inhaled insulin.
These include more general issues such as general dia-
betes worries, overall treatment satisfaction, and treat-
ment preference - all of which could apply to any
diabetes therapy and could potentially discriminate
among therapies, perceptions of insulin convenience,
ease of use, facilitation of self-care, and clinical efficacy -
which could apply to any insulin therapy and potentially
discriminate inhaled and injected insulin therapy, and
perceptions of the device used to deliver inhaled insulin
that could apply only to an inhaled insulin delivery sys-
tem. Thus the IITQ incorporates elements that allow for
comparisons among all diabetes therapies, among all
insulin therapies, and among all inhaled insulin therapies.
The IITQ was used in clinical trials of Technosphere
Insulin®. The Technosphere Insulin® (TI) system, a pro-
prietary product of MannKind Corporation, consists of
a dry powder formulationo fm o n o m e rh u m a n( r D N A
origin) mealtime insulin that is inhaled into the deep
lung using the MedTone Inhaler®, a pocket-sized, pas-
sive, breath-powered device [9-11]. In a previous rando-
mized, controlled trial, using an earlier version of the
IITQ (the ITQ), insulin naïve individuals with type 2
diabetes were randomized to active TI or placebo TI
therapy at mealtimes [12]. Perceptions of insulin therapy
improved significantly during the trial in the active TI
arm (effect size for overall measure = .56, p = 0.002) but
not in the placebo arm, with no significant difference
between arms. The majority of subjects rated inhaler
performance positively (median = 93% positive ratings).
The current study, which includes patients with type 1
diabetes and patients with type 2 diabetes, was designed
to assess the psychometric properties of the IITQ,
including: 1) dimensionality (i.e., subscales), 2) inter-
item agreement, 3) test-retest reliability, 4) floor/ceiling
effects, and 5) association of IITQ measures with study
participant characteristics.
Methods
Subjects and study protocol
Subjects providing data for this paper were drawn from
two multi-center, multi-national, 45-week studies con-
ducted by MannKind Corporation. Subjects in one study
were adults with type 1 diabetes randomized to meal-
time treatment with either TI or rapid-acting insulin
aspart as an adjunct to basal insulin therapy. Subjects in
t h es e c o n ds t u d yw e r ea d u l t s with type 2 diabetes ran-
domized to treatment with mealtime TI 2-3 times a day
and basal insulin, or treatment with biphasic insulin
aspart 70/30.
Inclusion criteria for both studies were: HbA1c >7.0%
and ≥ 11.0%, non-smoking, Forced Expiratory Volume
in 1 Second (FEV1) ≥ 70% predicted, Carbon monoxide
diffusing capacity (DLco) ≥ 80% predicted, Total Lung
Capacity (TLC) ≥ 80% predicted. Exclusion criteria for
all subjects were: history of viral and/or cirrhotic hepatic
disease and/or abnormal liver enzymes, history of
chronic obstructive pulmonary disease (COPD), asthma,
and/or any other clinically important pulmonary disease,
or evidence of severe complications of diabetes. Addi-
tional inclusion criteria for subjects with type 1 diabetes
were: current use of subcutaneous (sc) basal/prandial
insulin therapy, and BMI ≤ 35 kg/m
2. Additional inclu-
sion criteria for subjects with type 2 diabetes were: BMI
≤ 40 kg/m
2, and current use of sc insulin more than
once daily (with or without concomitant metformin or
thiazolidinediones). Additional exclusion criteria for sub-
jects with type 2 diabetes include use of sulfonylureas,
meglitindes, alpha glucosidase inhibitors, pramlintide
acetate, and/or incretins within the preceding 8 weeks.
Both studies complied with the Declaration of Hel-
sinki for participation in human research and received
appropriate institutional review board approvals prior to
initiation. All study participants gave written informed
consent before entering into the studies.
Subjects who provided consent, provided baseline
data, and completed the PRO measures were included
in the analyses reported here. Only those subjects who
answered all IITQ questions at both pre-treatment
administrations were included in this study.
Questionnaire development
The IITQ assesses: Diabetes Worries (5 questions), Per-
ceptions of Insulin Therapy (16 questions), Treatment
System Satisfaction (3 items), Treatment System Prefer-
ence (1 item) and Inhaler Performance (10 questions).
The IITQ appears in Additional file 1 (scoring instruc-
tions appear in Additional file 2). An earlier version of
the IITQ (the ITQ) included only 12 items assessing
perceptions of insulin therapy, and no items assessing
treatment system satisfaction, or treatment system
Rubin and Peyrot Health and Quality of Life Outcomes 2010, 8:32
http://www.hqlo.com/content/8/1/32
Page 2 of 8preference. Additional items in the current version
of the IITQ are: several perceptions of insulin therapy
(difficulty taking insulin at the right time, and effect of
insulin on overall glucose control, on high glucose
levels, and on low glucose levels); treatment system
satisfaction (overall satisfaction, willingness to continue
using the system, willingness to recommend the system
to others); treatment system preference (preference for
the system compared to the one previously used). Sev-
eral items measuring inhaler performance in the earlier
version were dropped from this version in order to
make it more broadly applicable to alternative inhaled
insulin devices.
The IITQ subscales assessing general diabetes worries,
perceptions of clinical efficacy, overall treatment satis-
faction, and treatment preference (i.e., all measures
except for perceptions of the insulin inhaler), were
based on the validated Insulin Delivery System Rating
Questionnaire (IDSRQ) [5]. The IDSRQ was developed
through a procedure in which focus groups were asked
about the advantages and disadvantages of the various
insulin delivery systems they used. Content validity of
the IITQ was assessed by cognitive debriefing methods,
to determine whether patients understand concepts and
items in the same way that the instrument’s developers
intended. The results of this effort, involving 15 patients
with type 1 or type 2 diabetes, indicated very few diffi-
culties with the IITQ, and no more than a small minor-
ity of study participants mentioned any given difficulty.
The IITQ was translated from English into the lan-
guages of each country in which each study was con-
ducted. IITQ translations were then back-translated into
English and these back-translations were reviewed by
the authors of this paper. When the back-translation dif-
fered from the original English version of the IITQ
the authors discussed these discrepancies with the trans-
lators in order to arrive at an IITQ translation that
w a sa sc l o s ea sp o s s i b l et ot he meaning of the original
English version.
Measures
In addition to a variety of clinical outcome measures,
participants in both studies completed the SF-36. This
instrument consists of 36 questions that generate two
composite scores, the Physical Component Summary
(PCS) and the Mental Component Summary (MCS).
QualityMetric performed the scoring analysis to gener-
ate scores ranging from 0 to 100, with higher scores
indicating better quality of life. The QualityMetric Miss-
ing Data Estimation algorithms were used to score all
SF-36 measures [13].
The IITQ was administered twice prior to treatment,
approximately 1-2 weeks apart, to assess test-retest relia-
bility. The IITQ was re-administered later in the study,
but for the most part, follow-up data are not analyzed
h e r e .H o w e v e r ,i t e m ss p e c i f ic to Inhaler Performance
could not be asked until the follow-up visits, so data
regarding these items are derived from the initial follow-
up administration of the IITQ. IITQ responses were
obtained during regularly scheduled visits, with standar-
dized timing and conditions of administration.
The IITQ assesses diabetes-specific, treatment-specific,
and device-specific, patient-reported outcomes in
patients using inhaled insulin. The IITQ differs from
other instruments designed to assess PRO associated
with inhaled insulin treatment [14,15]. The IITQ covers
a broad range of outcomes, as do comprehensive instru-
ments [16], but is shorter and contains items specific to
inhaled insulin.
Different versions of the IITQ were used pre-treat-
ment and at follow-up. The pre-treatment version did
not include inhaler perception items (items 26-35 in
Additional file 1) because participants would not have
used the inhaler at that time. Study participants rando-
mized to TI completed the entire questionnaire (items
1-35) at follow-up visits; study participants randomized
to rapid-acting insulin aspart (type 1 diabetes study) or
to biphasic insulin aspart (type 2 diabetes study) com-
pleted the same version of the IITQ at baseline and fol-
low-up visits (items 1-25). All IITQ items had a 6-point
response scale (strongly disagree = 0, disagree = 20,
mildly disagree = 40, mildly agree = 60, agree = 80,
strongly agree = 100). Where necessary, items were
reverse scored so that all were in the direction of greater
worries, more positive perceptions of insulin therapy,
higher treatment satisfaction and preference, and more
positive perceptions of inhaler performance. IITQ items
from each of the domains were combined into compo-
site additive scales for analysis.
Statistical analysis
Descriptive statistics (percentages, means, standard
deviations) are presented for participant characteristics
at baseline. Several psychometric analyses were per-
formed for the IITQ. Factor analyses were performed on
all IITQ domains with more than one item: Diabetes
Worries, Perceptions of Insulin Therapy, Treatment
Satisfaction and Inhaler Performance. Reliability (inter-
item agreement) was assessed by Cronbach’sa l p h af o r
both of the baseline administrations. Test-retest reliabil-
ity was assessed by the intraclass correlation coefficient
and paired t-tests for difference in means. Pearson cor-
relations were used to estimate associations of IITQ
scores from the initial administration with baseline sub-
ject characteristics (sex, race/ethnicity, age, weight, BMI,
A1c, duration of diabetes) and baseline SF-36 scores.
We did not expect strong correlations because there is
no hypothesized causal connection between the scales
Rubin and Peyrot Health and Quality of Life Outcomes 2010, 8:32
http://www.hqlo.com/content/8/1/32
Page 3 of 8and most correlates. We did expect better health status,
including SF-36 scores, to be associated with lower
IITQ worries scores and higher IITQ treatment satisfac-
tion scores. We expected low correlations between IITQ
subscale scores and other correlates; this would indicate
that IITQ responses are not heavily influenced by extra-
neous factors, making the IITQ appropriate for multiple
populations. Psychometric analyses were performed by
combining subjects in the trial treatment arms; separate
analyses were performed for the two study populations.
Minimum levels of statistical significance for all ana-
lyses were set at p < 0.05, two-tailed. All analyses were
conducted using SPSS 14.
Results
Study participants (Table 1) were 509 patients with type
1 diabetes and 567 participants with type 2 diabetes.
Participants were approximately evenly divided by gen-
der, and the majority was non-Hispanic White (84.5% of
type 1 and 66.0% of type 2). The mean age differed sub-
stantially between type 1 (37.4 years) and type 2
(55.4 years) populations. Mean duration of diabetes also
varied with study population (18.4 years for type 1 and
13.1 years for type 2). Type 2 patients were heavier than
type 1 participants (BMI = 31.4 kg/m
2 vs. 26.1 kg/m
2).
Glucose control was similar for type 1 and type 2
(A1c = 8.4% and 8.7%, respectively).
Factor analysis (results not shown) of items from the
Diabetes Worries and Treatment Satisfaction domains
revealed that each set of items formed only one factor;
therefore only a single score was generated for each of
these domains. Items from the Perceptions of Insulin
Therapy domain formed two distinct factors, one repre-
senting positively worded items and the other negatively
worded items. Because of the lack of substantive mean-
ing for the separate factors, only a single composite
scale was generated. Items from the Inhaler Perfor-
mance domain formed three distinct factors, one regard-
ing the device (5 items), another regarding the cartridge
(3 items), and a third regarding dosing (2 items);
because of the distinct substantive content, three com-
posite subscales were generated.
The primary assessment of reliability is reported in
Table 2. Inter-item agreement was acceptable for the
ITQ scales from the initial administration for type 1 and
type 2 participants (alphas = .71/.68 for Diabetes Wor-
ries, .85/.84 for Perceptions of Insulin Therapy, .83/.81
for Treatment Satisfaction). The results were similar for
the retest administrations (alphas = .75/.70 for Diabetes
Worries, .87/.86 for Perceptions of Insulin Therapy,
.85/.85 for Treatment Satisfaction).
Test-retest reliability was assessed in two ways: mean
change and correlations across the two pretreatment
administrations. Three of the eight tests of change in
means were significant (Perceptions of Insulin Therapy
and Treatment Preference for type 1 and Diabetes Wor-
ries for type 2), but the size of the change was small
(less than 0.1 standard deviation units, a measure of
effect size). The test-retest associations were acceptable
for type 1 and type 2 participants (.81/.77 for Diabetes
Worries, .90/.85 for Perceptions of Insulin Therapy, .83/
.85 for Treatment Satisfaction, .73/.67 for Treatment
Preference).
For the three multi-item scales administered at base-
line there was little in the way of floor/ceiling effects;
across both pre-treatment administrations in both study
populations the percentage of participants with mini-
mum scores ranged from 0.2% to 2.8%, and the percen-
tage with maximum scores ranged from 0% to 9.3%. For
the single-item measure minimum scores ranged from
3.5% to 7.4%, and the percentage with maximum scores
ranged from 11.6% to 21.0%.
Associations among IITQ scale scores varied within
and between populations. Diabetes Worries were not
associated with any other score in the type 1 population,
but were significantly associated with Treatment Satis-
faction and Treatment Preference in the type 2 popula-
tion (r = .12 and .14, respectively). Associations among
Table 1 Study Population Baseline Characteristics
Characteristic Type 1 Study
(n = 509)
Type 2 Study
(n = 567)
Gender, N (%)
Male 267 (52.5) 271 (47.8)
Female 242 (47.5) 296 (52.2)
Race, N (%)
Non-Hispanic White 430 (84.5) 374 (66.0)
African American 33 (6.5) 49 (8.6)
Asian American 6 (1.2) 11 (1.9)
Hispanic 33 (6.5) 121 (21.3)
Other 7 (1.4) 12 (2.1)
Age, Years
Mean (SD) 37.4 (13.0) 55.4 (10.2)
Duration of Diabetes, Years
Mean (SD) 18.4 (11.6) 13.1 (7.5)
Weight, Kilograms
Mean (SD) 76.6 (15.1) 87.8 (17.7)
BMI, kg/m2
Mean (SD) 26.1 (3.8) 31.4 (4.8)
HbA1c (%)
Mean (SD) 8.4 (1.0) 8.7 (1.1)
SF-36 PCS
Mean (SD) 53.3 (6.5) 46.7 (9.2)
SF-36 MCS
Mean (SD) 50.3 (9.0) 49.2 (10.9)
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size (r = .29 to .58, median = .46).
Associations of ITQ measures with subject character-
istics are presented in Table 3. The magnitude of all sig-
nificant correlations was modest. The Diabetes Worries
measure was significantly lower for patients who were
non-Hispanic White and had higher weight/BMI (type 1
and type 2), and those who had better mental health
(type 2 only). The Perceptions of Insulin Therapy mea-
sure was significantly higher for patients who were male
and older (type 2 only) and who had better mental or
physical health (type 1 and type 2). The Treatment
Satisfaction measure was significantly higher for patients
who were older and had lower weight/BMI and better
physical health (type 2 only) and those who had better
glucose control (type 1 and type 2). The Treatment
Table 2 Scale Statistics
T1 T1 T1 T2 T2 T2
Measure (# of items) Test Retest Test-Retest Test Retest Test-Retest
Diabetes Worries (5)
Mean
a 74.0 74.5 p = .348 75.2 76.8 p = .009
SD 16.7 16.9 17.4 16.2
% max, % min 0.2,7.7 0.6,8.1 0.4,9.0 0.4,9.3
Reliability
b .71 .75 .81 .68 .70 .77
Perceptions of Insulin Therapy (16)
Mean
a 58.2 56.9 p = .001 57.0 56.4 p = .191
SD 14.9 15.0 15.9 15.9
% max, % min 0.2,0.0 0.2,0.0 0.2,0.0 0.2,0.7
Reliability
b .85 .87 .90 .84 .86 .85
Treatment Satisfaction (3)
Mean
a 53.3 54.1 p = .285 52.5 53.6 p = .248
SD 21.4 21.2 23.9 24.6
% max, % min 2.2,1.6 1.8,1.8 2.8,2.8 2.3,4.6
Reliability
b .83 .85 .83 .81 .85 .74
Treatment Preference (1)
Mean
a 69.2 66.8 p = .020 58.1 58.3 p = .887
SD 26.0 25.3 30.3 29.0
% max, % min 3.7,21.0 3.5,16.9 7.4,13.8 6.9,11.6
Reliability
b na na .73 na na .67
a Test-Retest is the p-value for paired t-test of difference in means across administrations.
b Reliability for each administration is Cronbach’s alpha (na = not applicable); Test-Retest reliability is the intraclass correlation coefficient.
Table 3 Association of IITQ Measures with Participant Characteristics at Baseline
Treatment Outcome Diabetes Worries Perceptions of Insulin Therapy Treatment Satisfaction Treatment Preference
Gender (Male = 1) -.08/-.05 -.00/.08* .03/.06 -.01/.01
Race (Caucasian = 1) -.18***/-.10* .04/.02 .08/.03 .03/.07
Age (Years) -.03/-.04 -.04/.09* .03/.12** -.02/.06
Duration of Diabetes (Years) -.05/03 .01/.05 .02/.03 .07/.08
Weight (Kilograms) -.16***/-.16 *** -.06/-.05 -.00/-.09* -.05/-.11**
BMI (kg/m2) -.11*/-.09* -.05/-.07 -.01/-.09* -.05/-.12**
A1c (%) .00/.01 -.03/-.06 -.14**/-.11** -.01/-.07
SF-36 PCS -.07/.02 .13**/.14*** .04/.09* .00/.08
SF-36 MCS -.09/-.12** .15***/.17*** .08/-.01 .11*/.01
Note: Cell entries are Pearson correlations (type 1/type 2).
*p<. 0 5
** p < .01
*** p < .001
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who had lower weight/BMI (type 2 only) and better
mental health (type 1 only).
For the Inhaler Performance items (obtained only at fol-
low-up and only from study participants randomized to
TI) the scale reliabilities were acceptable for type 1 and
type 2 participants (alphas = .86/.90 for Overall, .81/.84
for Device, .86/.88 for Cartridge, .73/.79 for Dosing). Test-
retest reliability was not assessed for the device perfor-
mance measures because these items could not be
administered until after patients had used the device.
Floor effects were nonexistent for all measures in both
type 1 and type 2 populations (% receiving minimum
score = 0%). Ceiling effects (type 1/type 2) were minimal
to modest for the overall measure and the dose subscale
(% receiving maximum score = 4.9%/7.7% and 6.8%/10.6%,
respectively) but higher for the device subscale and the
cartridge subscale (10.7%/19.1% and 36.1%/39.0%,
respectively).
Associations among Inhaler Performance subscale
scores were moderate to large (r = .28 to .68, median =
.52). Associations with baseline participant characteris-
tics were not assessed because they reflect differential
efficacy rather than differences in response patterns
(because these measures were obtained after use of the
device).
Discussion
The results of this study provide evidence that the IITQ
is a reliable instrument for assessing a broad range
of patient reported outcomes (PRO) in patients with
type 1 or type 2 diabetes using inhaled insulin. In addi-
tion to a measure of diabetes worries, the IITQ also
includes measures of perceptions of insulin therapy,
treatment system satisfaction, treatment system prefer-
ence, and inhaler performance.
Including insulin treatment-specific measures in an
assessment is important because these measures are
likely to be more sensitive to specific but important dif-
ferences among insulin treatment systems. Device-speci-
fic measures are also useful, because device usability
may affect adoption of a medication treatment system
and persistent use of the system.
Incorporating multiple indicators of treatment system
satisfaction and a measure of treatment preference not
only allows comparison of the system patients previously
used with the one they are currently using, but also pro-
vides a prospective measure of overall satisfaction with
the current system, interest in continuing to use the sys-
tem, and willingness to recommend the system to
others. Although the IITQ is specifically designed to
assess PRO related to insulin therapy, the system satis-
faction and system preference items refer to any system
for controlling blood glucose levels, so these measures
can be used to compare any such treatment systems,
including oral agents or injectable agents other than
insulin.
The IITQ covers a broader range of outcomes than
other instruments designed to assess general diabetes
treatment satisfaction (DTSQ) or PRO associated with
inhaled insulin therapy [14,15]. The IITQ assesses many
of the same elements as the IDSRQ [16], including com-
fort, convenience, facilitation of self-care, and clinical
efficacy, but it is shorter, and it contains items specific
to inhaled insulin therapy.
The IITQ has acceptable psychometric properties
(internal consistency, test-retest reliability, floor/ceiling
effects). Although the test-retest analysis revealed statis-
tically significant changes in means for three of eight
tests, the shifts were small, less than 0.1 SD units [17].
Test-retest reliability was not assessed for the device
performance measures because this was not possible
given the fact that these items could not be adminis-
tered until after patients had used the device.
IITQ measures were significantly associated with a
number of study participant characteristics, though all
these associations were of modest magnitude. Given the
absence of hypothesized causal connections between
IITQ subscales and most correlates, we did not expect
strong correlations. We did expect better health status,
including SF-36 scores to be associated with lower IITQ
worries scores and higher IITQ treatment satisfaction
scores. These associations were significant for diabetes
worries and SF-36 mental health scores, and for treat-
ment satisfaction and SF-36 physical health scores in
patients with type 2 diabetes. We also found more posi-
tive perceptions of insulin therapy in individuals with
higher SF-36 physical health and mental health scores.
These findings correspond to those of a recent study of
individuals taking insulin which found that lower levels
of general wellbeing and higher levels of diabetes dis-
t r e s sw e r ea s s o c i a t e dw i t hm o r en e g a t i v ep e r c e p t i o n so f
insulin therapy [18]. Several studies of insulin naïve
individuals have found significant associations between
poor wellbeing or distress and negative perceptions of
insulin therapy [19-21].
We also found higher levels of treatment satisfaction
among those with lower levels of HbA1c. It is not sur-
prising that individuals whose treatment is associated
with good blood glucose have positive perceptions of
that treatment. We did find one unexpected association
between an IITQ measure (diabetes worries) and a mea-
sure of health status (BMI): diabetes worries were lower
in those with higher BMI. Perhaps lower levels of dia-
betes worry led to less active diabetes self-care, and con-
sequently to higher BMI.
As expected, we found few significant correlations
between IITQ subscale score and other participant
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heavily influenced by extraneous factors, making the
IITQ appropriate for multiple populations.
Study strengths and limitations
Study strengths include the large study populations of
individuals with type 1 diabetes and those with type 2
diabetes. Another strength is the standardized instru-
ment administration procedures. Study limitations
include the relative lack of racial/ethnic diversity among
study participants.
Research implications
Future research with the IITQ should include confirma-
tory psychometric analyses in representative populations,
and longitudinal studies to assess other psychometric
properties of the IITQ, especially the instrument’s valid-
ity (e.g., construct validity as assessed by known group
comparison, criterion validity as assessed by reference to
a gold standard measure, and predictive validity as
assessed by subsequent continuation of the study medi-
cation). Of special interest will be studies that assess
objective clinical outcomes and patient perception mea-
sures that predict treatment satisfaction and treatment
preference; the benefits of such analyses are described
elsewhere [22,23].
Conclusions
In summary, this study provides evidence that the IITQ
is a reliable instrument for assessing a broad range of
patient reported outcomes in individuals with type 1 or
type 2 diabetes, especially those taking inhaled insulin.
Future research should further assess this instrument’s
validity and its suitability for other research situations.
Additional file 1: Appendix A: IITQ
Additional file 2: Appendix B: IITQ Scoring Instructions
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